CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cardiodx (Assignment for the Benefit of Creditors), LLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cardiodx (Assignment for the Benefit of Creditors), LLC
600 Saginaw Drive
Phone: (650) 475-2788p:650 475-2788 Redwood City, CA  94063-4751  United States Fax: (650) 475-2799f:650 475-2799

CardioDx Inc filed a Registration Withdrawal Request of its Form S-1 (File No. 333-191698) with the SEC on 12/23/2014. The company believes the marketplace is not sufficiently attractive to proceed with the offering.
On 1/23/2019, CardioDx Inc. filed an application for an Assignment for the Benefit of Creditors with the State of California. Michael A Maidy was assigned to Cardiodx (Assignment for the Benefit of Creditors), LLC as the Liquidator.

Business Summary
Cardiodx (Assignment for the Benefit of Creditors), LLC, formerly known as CardioDx, Inc. is a United States-based molecular diagnostics company. The Company specializes in cardiovascular genomics. It is focused on coronary artery disease and is engaged in expanding patient access and managing healthcare through the commercialization of genomic technologies. It provides Corus CAD, a blood test that helps clinicians to assess whether or not their patients' chest discomfort or other symptoms may be due to obstructive coronary artery disease (CAD). The Corus CAD test is a tool that can help identify patients unlikely to have obstructive CAD as the cause of the patient's symptoms and help clinicians determine appropriate next steps for patient management. The Corus CAD algorithm integrates age, sex and gene expression to calculate a score. Combining the Corus CAD score with other patient information provides clinicians with a picture of their patient's CAD status through the test's clinical validity in identifying patients unlikely to have obstructive CAD.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201312/31/2012YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director KhushMehta 6/1/2016 6/1/2016
Chief Financial Officer Timothy G.Henn 12/14/2015 12/14/2015
Senior Vice President of Sales EricSandberg
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 138 (As of 9/30/2013)
Outstanding Shares: 17,101,086 (As of 11/4/2013)
Stock Exchange: BER
Federal Tax Id: 651198370
Fax Number: (650) 475-2799
Email Address: info@cardiodx.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023